{"id":"rabeprazol","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Disease of liver","Fracture of bone","Hypomagnesemia","Osteoporosis"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00989300","NCT05571787","NCT03143166","NCT00511745","NCT00511966"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Rabeprazol","companyId":"janssen-cilag-s-a","ecosystem":[],"mechanism":{"target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Janssen-Cilag, S.A.","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Rabeprazol","indications":{"approved":[{"name":"Duodenal Ulcer due to H. Pylori","diseaseId":"duodenal-ulcer-due-to-h.-pylori","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Duodenal ulcer disease","diseaseId":"duodenal-ulcer-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastroesophageal reflux disease","diseaseId":"gastroesophageal-reflux-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Maintenance of Healing Gastroesophageal Reflux","diseaseId":"maintenance-of-healing-gastroesophageal-reflux","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Multiple endocrine adenomas","diseaseId":"multiple-endocrine-adenomas","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pathological Gastric Hypersecretory Condition","diseaseId":"pathological-gastric-hypersecretory-condition","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Peptic ulcer","diseaseId":"peptic-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic mast cell disease","diseaseId":"systemic-mast-cell-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Zollinger-Ellison syndrome","diseaseId":"zollinger-ellison-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00989300","phase":"Phase 1","title":"Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel. A Prospective, placebo-and Active Treatment-controlled, Open Label, Randomized 3-way Cross Over Study in Healthy Su","status":"COMPLETED","sponsor":"Janssen Cilag S.A.S.","isPivotal":false,"enrollment":39,"indication":"Healthy","completionDate":"2010-03"},{"nctId":"NCT05571787","phase":"Phase 1","title":"A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hutchmed","isPivotal":false,"enrollment":26,"indication":"Relapsed or Refractory Lymphoma","completionDate":"2022-09-22"},{"nctId":"NCT03143166","phase":"Phase 1","title":"Relative Bioavailability of Tablet Formulation of Dabigatran Etexilate With and Without Co-administration of Rabeprazole in Healthy Male Subjects (an Open-label, Single-dose, Two-period, Single-arm St","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":36,"indication":"Non-alcoholic Fatty Liver Disease","completionDate":"2017-08-02"},{"nctId":"NCT00511745","phase":"N/A","title":"Safety of Rabeprazole in Patients Under Multiple Treatments","status":"TERMINATED","sponsor":"Janssen-Cilag, S.A.","isPivotal":false,"enrollment":2157,"indication":"Gastroesophageal Reflux, Gastric Ulcer","completionDate":"2002-11"},{"nctId":"NCT00511966","phase":"N/A","title":"Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol","status":"TERMINATED","sponsor":"Janssen-Cilag, S.A.","isPivotal":false,"enrollment":1049,"indication":"Gastroesophageal Reflux","completionDate":"2002-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Gastroenterology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}